Sara Barulli

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project

Elisabetta Abruzzese, Monica Crugnola, Luca Garuffo, Uroš Markovic et autres

Background: Since the advent of imatinib, more potent next-generation tyrosine kinase inhibitors (TKIs) and asciminib have expanded therapeutic options for chronic myeloid leukemia (CML). Treatment-free remission (TFR) is an important goal in CML management, but only ~30% of patients can achieve it, …

it (code pays fourni par la source)

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Elisabetta Abruzzese, Simona Bernardi, Uroš Markovic, Malgorzata Monika Trawinska et autres

Since the introduction of imatinib, 2nd and 3rd-generation Tyrosine Kinase Inhibitors (TKIs) with greater potency have expanded CML treatment options. Recently, the allosteric inhibitor Asciminib (ASC) has been introduced. While the goal is to achieve treatment-free remission (TFR) for all patients, only …

it, ch (code pays fourni par la source)

COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report

Massimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, Immacolata Attolico et autres

Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February …

it (code pays fourni par la source)

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

Federica Loscocco, Giuseppe Visani, Annamaria Ruzzo, Irene Bagaloni et autres

Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of CML patients achieving deep and …

it, ca (code pays fourni par la source)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Massimo Breccia, Elisabetta Abruzzese, Monica Bocchia, Massimiliano Bonifacio et autres

it (code pays fourni par la source)

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, Francesco Albano et autres

Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as …

it (code pays fourni par la source)

Single shot medium dose melphalan in resistant/relapsed myeloma: a bridge to target therapies?

Cristina Clissa, Federica Loscocco, Alessandro Isidori, Sara Barulli et autres

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine

Giuseppe Visani, Federica Loscocco, A. Ruzzo, Sara Galimberti et autres

We evaluated the impact of genomic polymorphisms in folate-metabolizing, DNA synthesis and DNA repair enzymes on the clinical outcome of 108 patients with myelodysplastic syndromes (MDS) receiving best supportive care (BSC) or azacitidine. A statistically significant association between methylenetetrahydrofolate reductase (MTHFR) 677T/T, …

it (code pays fourni par la source)

Assessment of the interlaboratory variability and robustness of JAK2 V617F mutation assays: A study involving a consortium of 19 Italian laboratories

Margherita Perricone, Francesca Palandri, Emanuela Ottaviani, Mario Angelini et autres

// Margherita Perricone 1 , Francesca Palandri 1 , Emanuela Ottaviani 1 , Mario Angelini 2 , Laura Bagli 3 , Enrica Bellesia 4 , Meris Donati 5 , Donato Gemmati 6 , Patrizia Zucchini 7 , Stefania Mancini 8 , Valentina …

it (code pays fourni par la source)

Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes

Federica Loscocco, Giuseppe Visani, Elisa Giacomini, Annamaria Ruzzo et autres

Abstract Background: Several studies have suggested that genetic variability related with single nucleotide polymorphisms (SNPs) of the BER system, DNA synthesis and folate-metabolizing pathway genes could modulate DNA repair capacity. Moreover, these genes are supposed to be related to cancer risk. However, …

it, ca (code pays fourni par la source)

Advancement in high dose therapy and autologous stem cell rescue in lymphoma.

Alessandro Isidori, Cristina Clissa, Federica Loscocco, Barbara Guiducci et autres

Although advanced stage aggressive non-Hodgkin's lymphomas and Hodgkin's disease are thought to be chemotherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission. High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is often the only possibility …

at (code pays fourni par la source)

251 TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK

Giuseppe Visani, Federica Loscocco, A. Ruzzo, Maria Teresa Voso et autres